BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
search help
Documents 1-6 out of 6 found
  Current Search:  daranide: 7, dichlorphenamide: 12  
100%
PDF
Specificity Table TOX.xls
Tested (ng/ ml) Combipress Chlorthalidone Diuretic 100,000 Compazine Prochlorperazine Antiemetic 100,000 Contralac Metergoline Prolactin inhibitor 100,000 Cordarone Amiodarone Antiarrhythmic 100,000 Cordran Flurandrenolide Glucocorticoid 100,000 Cortazac Hydrocortisone Glucocorticoid 100,000 Cortazac metabolite Hydrocortisone metab.( Cortol, ss-) Hydrocortisone metabolite 100,000...

author: Biosite Incorporated
Matching: daranide dichlorphenamide Find similar documents More document info

100%
PDF
Specificity Table TOX.xls page 7


author: Biosite Incorporated
Matching: daranide dichlorphenamide Find similar documents More document info

100%
TEXT
http://www.fda.gov/cder/orange/appendix_a.txt
45, DIHYDROERGOTAMINE MESYLATE DACARBAZINE, DACARBAZINE DALGAN, DEZOCINE DALMANE, FLURAZEPAM HYDROCHLORIDE DANAZOL, DANAZOL DANOCRINE, DANAZOL DANTRIUM, DANTROLENE SODIUM DAPSONE, DAPSONE DARANIDE, DICHLORPHENAMIDE DARAPRIM, PYRIMETHAMINE DARBID, ISOPROPAMIDE IODIDE DARICON, OXYPHENCYCLIMINE HYDROCHLORIDE DARVOCET A500, ACETAMINOPHEN DARVOCET, ACETAMINOPHEN DARVOCET-N 100...

Matching: daranide dichlorphenamide Find similar documents More document info
100%
HTML
Prescription and Over-the-Counter Drug Product List: 5/2003
ADDITIONS/DELETIONS FOR PRESCRIPTION DRUG PRODUCT LIST ACETAMINOPHEN; BUTALBITAL; CAFFEINE TABLET; ORAL BUTALBITAL, APAP, AND CAFFEINE -A- AB AXIOM PHARM 325MG;50MG;40MG N89536 001 FEB 16, 1988 MAY CAHN -D- AB HALSEY 325MG;50MG;40MG N89536 001 FEB 16, 1988 MAY CAHN ACETAMINOPHEN; HYDROCODONE BITARTRATE TABLET; ORAL HYDROCODONE BITARTRATE AND ACETAMINOPHEN -A- AA ABLE 500MG;7.5MG...
author: AUTHOR
Matching: daranide dichlorphenamide Find similar documents More document info
51%
PDF
OP2 outline v2
INNOVATIONS IN OPHTHALMIC PHARMACEUTICALS, 1996Ð 2005 Chapter 1: Executive Summary Research and Development Environment Demographics Major Markets Chapter 2: Introduction Study Objectives Scope and Organization Part I: Environment Part II: Disease and Products Overview Part III: Strategic ...

author: Dan
Matching: daranide Find similar documents More document info

51%
PDF
OP2 outline v2 page 1
INNOVATIONS IN OPHTHALMIC PHARMACEUTICALS, 1996Ð 2005 Chapter 1: Executive Summary Research and Development Environment Demographics Major Markets Chapter 2: Introduction Study Objectives Scope and Organization Part I: Environment Part II: Disease and Products Overview Part III: Strategic ...

author: Dan
Matching: daranide Find similar documents More document info

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.